FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to pharmaceutical composition for treatment of disease, condition or disturbance requiring application of the antagonist of the neurokinin receptor containing therapeutically effective quantity of compound of the formula I 
or its pharmaceutically acceptable salt where the composition contains sulphopropyl ether of β-cyclodextrin, meta-cresol preservative and pharmaceutically acceptable medium. Also, the invention refers to application of the said composition and a method for treatment way of diseases requiring application of the antagonist of the neurokinin receptor.
EFFECT: maintenance of stability of a compounding and acceptable tolerance in the place of the product injection when using preservative for prevention of bacteriemic and fungoid growth in a compounding.
11 cl, 4 dwg, 9 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INHALATION COMPOSITION CONTAINING SULFOALKYL ETHER | 2004 |
|
RU2388462C2 |
| SOLID PHARMACEUTICAL PREPARATIVE FORMULATIONS WITH CONTROLLED RELEASE BASED ON CYCLODEXTRIN SULFOALKYL ESTERS | 2000 |
|
RU2233176C9 |
| INHALATION FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRIN AND CORTICOSTEROID | 2004 |
|
RU2390330C2 |
| COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR, COMPOSITION OF RAS-FARNESYLT RANSFERASE INHIBITOR, PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2230062C2 |
| FORMULATIONS OF 2-IMINOBIOTINE AND USE THEREOF | 2011 |
|
RU2627460C2 |
| FORMULATIONS OF INTRAVENOUS SOLUTIONS OF POSACONAZOLE STABILISED BY SUBSTITUTED BETA-CYCLODEXTRINE | 2011 |
|
RU2575768C2 |
| COMPOSITIONS OF ALKYLATED CYCLODEXTRIN AND METHODS OF THEIR PREPARATION AND APPLICATION | 2013 |
|
RU2747757C2 |
| COMPOSITIONS CONTAINING ACETAMINOPHENE AND CYCLODEXTRIN SULFAOKYL ETHER | 2017 |
|
RU2772384C2 |
| LIPOSOME HAVING INNER AQUEOUS PHASE AND CONTAINING SULPHOBUTYL ESTER CYCLODEXTRIN SALT | 2010 |
|
RU2575793C2 |
| AQUEOUS PHARMACEUTICAL COMPOSITIONS BASED ON 1,2-DIHYDROPYRIDINE COMPOUNDS | 2019 |
|
RU2824582C2 |
